2010
DOI: 10.9769/epj.2010.2.1.bs
|View full text |Cite
|
Sign up to set email alerts
|

Changes on Self-Report Measures of Public Speaking Anxiety Following Treatment With Thought Field Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
11
0
3

Year Published

2012
2012
2016
2016

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(16 citation statements)
references
References 17 publications
2
11
0
3
Order By: Relevance
“…While Division 12 has not yet evaluated any of the evidence for energy psychology in published reports, clinical conditions for which acupoint stimulation protocols appear-based on the studies presented above-to meet the criteria for designation as a "well-established treatment" include phobias (Wells, et al, 2003;Salas, Brooks, & Rowe, 2011) and test-taking anxiety (Rubino, in press;Sezgin & Özcan, 2009). Acupoint protocols appear to meet the criteria for designation as a "probably efficacious treatment" for PTSD (Church et al, 2011;Church, Hawk et al, in press;Connolly and Sakai, 2011;Karatzias et al, 2011), depression (Brattberg, 2008;Church, De Asis, et al, in press;Karatzias et al, 2011), and public speaking anxiety (Schoninger and Hartung, 2010;Jones, Thornton, & Andrews, 2011).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…While Division 12 has not yet evaluated any of the evidence for energy psychology in published reports, clinical conditions for which acupoint stimulation protocols appear-based on the studies presented above-to meet the criteria for designation as a "well-established treatment" include phobias (Wells, et al, 2003;Salas, Brooks, & Rowe, 2011) and test-taking anxiety (Rubino, in press;Sezgin & Özcan, 2009). Acupoint protocols appear to meet the criteria for designation as a "probably efficacious treatment" for PTSD (Church et al, 2011;Church, Hawk et al, in press;Connolly and Sakai, 2011;Karatzias et al, 2011), depression (Brattberg, 2008;Church, De Asis, et al, in press;Karatzias et al, 2011), and public speaking anxiety (Schoninger and Hartung, 2010;Jones, Thornton, & Andrews, 2011).…”
Section: Discussionmentioning
confidence: 99%
“…Determining the magnitude of an effect is accomplished by a calculation of the effect size, often as "Cohen's d" or "eta squared" (Cohen, 1998). Seven of the eight studies that reported Cohen's d (Baker & Siegel, 2010;Church, De Asis et al, in press;Irgens et al, in press;Karatzias et al, 2011;Salas et al, 2011;Schoninger & Hartung, 2010;Wells et al, 2003) had at least one salient clinical outcome with d > .8, indicating large effect sizes. The other study (Stapleton et al, 2012) reported a moderate effect size.…”
Section: Use Of Placebo or Active Ingredient Comparison Conditionsmentioning
confidence: 99%
See 2 more Smart Citations
“…Where means and standard deviations were not available in the study (Jones, Thornton, & Andrews, 2010;Schoninger & Hartung, 2010;Waite & Holder, 2003), other statistics (sample size and pvalue) were used to calculate the effect size using Comprehensive Meta-Analysis software (CMA) version 2.2057 (Borenstein, Hedges, Higgins, & Rothstein, 2009). In a number of studies standard error (SE) was reported and this was converted to standard deviation (SD) by multiplying the SE by the square root of the sample size minus one.…”
Section: Analysesmentioning
confidence: 99%